Director of Regulatory Affairs

Proton Intelligence is developing a continuous potassium monitoring product.

Overview

The Director of Regulatory Affairs will lead Proton Intelligence’s regulatory function and own its regulatory strategy, company position and execution for its first continuous potassium monitoring product. Working with product, clinical, technical and quality leaders, the Director will translate the strategy into evidence requirements, lead agency interactions and submissions, and turn specialist advice and agency feedback into implemented development decisions. This is a hands-on leadership role: success means a defensible regulatory path, evidence that supports the intended claims, delivery against the agreed programme, and clear internal ownership of regulatory judgement and follow-through.

Key Responsibilities

Regulatory strategy, intended use & evidence

  • Own and maintain the regulatory strategy with product, clinical and technical leaders, clarifying intended use, claims, target populations, key agency questions and the proposed submission pathway.
  • Identify material uncertainties and compare options by their evidence burden, development effort, timing and effect on the product’s usefulness; bring recommendations to leadership.
  • Maintain a current map of applicable regulatory requirements and relevant standards, explaining their practical implications for the development and clinical programmes.

Requirements & development integration

  • Translate the strategy into specific requirements for clinical protocols, performance evaluation, reference and calibration approaches, verification and validation, risk management, usability, software, manufacturing and labelling.
  • Work with functional owners to connect claims and submission needs to planned evidence, identifying gaps early and agreeing how they will be resolved.
  • Assess the regulatory implications of product, study and development changes and ensure approved decisions are reflected in the regulatory file and integrated programme plan.

Agency interactions & submissions

  • Serve as Proton’s primary regulatory interface with FDA, leading the planned Pre-Submission programme from question formulation and briefing documents through meeting preparation, records and follow-up.
  • Assess and, if supported by the strategy and evidence, prepare a Breakthrough Device designation request with specialist input where required.
  • Own the regulatory workplan, decision log and critical path, including submission content, authors, reviews, dependencies, budget and resourcing; maintain a coherent submission narrative and resolve inconsistencies before filing.

Consultant direction & internal judgement

  • Select and direct regulatory consultants and other specialists through clear questions, scopes, deliverables, budgets and review dates; critically assess their advice and recommend when additional internal capability is needed.
  • Integrate specialist contributions into one defensible company position, documenting assumptions, alternative interpretations and decisions that require executive judgement.
  • Coordinate regulatory input across teams and remove routine follow-up from executives, escalating consequential decisions with a recommendation and the evidence needed to decide.

Execution, records & cross-functional ownership

  • Turn agency feedback into specific changes to evidence plans, requirements and development work, with named owners and follow-through to completion.
  • Work with Quality to maintain controlled, traceable regulatory records and submission evidence; align regulatory readiness with the company’s design and quality processes.
  • Provide concise, decision-oriented updates to leadership and the board on the regulatory path, evidence gaps, risks, milestones and required decisions; support fundraising and partner diligence as needed. Scientific, clinical, product and quality owners retain their respective responsibilities.

Required Skills & Qualifications

  • Substantial medical-device regulatory experience, including direct ownership of U.S. FDA strategy and hands-on leadership of Q-Sub/Pre-Submission programmes and submissions for novel or complex devices in a development-stage organisation.
  • Demonstrated examples of FDA interactions that materially shaped evidence requirements, study design, product decisions or submission strategy, with the ability to turn agency advice into practical development requirements.
  • Strong working knowledge of FDA device pathways, including IDE planning and De Novo strategy, and of the interfaces with clinical evidence, design controls, performance testing, reference methods, software, risk management, usability, manufacturing and labelling.
  • Excellent technical writing and critical-reading skills, with the ability to assemble a clear, internally consistent submission and distinguish evidence, assumptions and proposed interpretations.
  • Experience directing specialist consultants while retaining internal ownership of the company position, decisions and follow-through.
  • Sound judgement under uncertainty, constructive challenge and strong cross-functional communication; able to work hands-on while developing a longer-term regulatory plan.
  • A degree in science, engineering, regulatory affairs or a related discipline, or equivalent relevant experience. Experience with wearable sensors, in vitro diagnostics or physiological monitoring is helpful; regulatory certification is an advantage.

Near-Term Success Measures

  • Within 30 days, complete a review of the current regulatory file, consultant work and upcoming interactions, and agree ownership, priorities and the most consequential open questions.
  • Within 90 days, establish a leadership-agreed strategy and evidence-gap plan connecting intended use, claims, agency questions and development work.
  • Within 90 days, establish an agreed regulatory delivery plan with submission and interaction dates, evidence-gap closure milestones, named owners, dependencies, budget and specialist resource needs.
  • Within 6 months, complete and submit the regulatory packages due under the agreed programme to the required standard, and translate agency feedback received into assigned development changes with agreed completion dates.
  • Within 6 months, close the evidence gaps and implement the agency-driven changes due under the agreed programme, with traceable evidence of completion; keep leadership informed of remaining risks, decisions and any changes to the regulatory critical path.

Clinical

Clayton, Australia

Partager sur :